Diving into Price-to-Book (P/B) Ratios for Health Stocks 💉

The P/B ratio compares a stock's market price to its book value—great for benchmarking against competitors or historical trends. And potentially can be used to find value stocks.
HOWEVER, a low P/B could mean it's undervalued... or just a dud. Always dig deeper!

I crunched numbers via Finchat on some health giants I've been eyeing. Here's the scoop:
- Eli Lilly (LLY): Sky-high P/B of 48.9—trading at a massive premium. But I like their Tirzepatide Zepbound product. Tons of profit potential from obesity.
- Novo Nordisk (NVO): P/B of 14.5—still premium, but not as wild as Lilly. Hello Ozempic!
- Pfizer (PFE): Moderate P/B of 5.8—middle of the pack among peers.

Benchmarks:
- S&P 500 Health Care Index: 4.72
- S&P Insurance Select Industry Index: 1.66 (I put here insurance because UNH business is in part insurance)

Check out this table for the full deets (as of Q1 2025).
Any thoughts?